Treatment of COVID-19-associated ARDS with umbilical cord-derived mesenchymal stromal cells in the STROMA-CoV-2 multicenter randomized double-blind trial: long-term safety, respiratory function, and quality of life

Background The STROMA-CoV-2 study was a French phase 2b, multicenter, double-blind, randomized, placebo-controlled clinical trial that did not identify a significant efficacy of umbilical cord-derived mesenchymal stromal cells in patients with SARS-CoV-2-induced acute respiratory distress syndrome. Safety on day 28 was found to be good. The aim of our extended study was to assess the 6- and 12-month safety of UC-MSCs administration in the STROMA-CoV-2 cohort. Methods A detailed multi-domain assessment was conducted at 6 and 12 months following hospital discharge focusing on adverse events, lung computed tomography-scan, pulmonary and muscular functional status, and quality of life in the STROMA-CoV-2 cohort including SARS–CoV-2-related early (< 96 h) mild‐to-severe acute respiratory distress syndrome. Results Between April 2020 and October 2020, 47 patients were enrolled, of whom 19 completed a 1-year follow-up. There were no significant differences in any endpoints or adverse effects between the UC-MSCs and placebo groups at the 6- and 12-month assessments. Ground-glass opacities persisted at 1 year in 5 patients (26.3%). Furthermore, diffusing capacity for carbon monoxide remained altered over 1 year, although no patient required oxygen or non-invasive ventilatory support. Quality of life revealed declines in mental, emotional and physical health throughout the follow-up period, and the six-minute walking distance remained slightly impaired at the 1-year patient assessment. Conclusions This study suggests a favorable safety profile for the use of intravenous UC-MSCs in the context of the first French wave of SARS-CoV-2-related moderate-to-severe acute respiratory distress syndrome, with no adverse effects observed at 1 year.

nasal inspiratory pressure (SNIP)), alongside patientreported outcome measures of quality of life (36-Item Short Form Survey (SF-36) and EuroQol 5 Dimension 5 Level survey (EQ-5D)).CT-scans at both end-inspiration and end-expiration were evaluated by two chest radiologists for the presence of pulmonary abnormalities [2].Physical performance was also assessed using the 6-min walking test (6-MWT) [3], during which dyspnea and perceived exertion were quantified using the Borg scale [4,5].
Continuous variables were described using their means and standard deviations and with frequencies and percentages for categorical variables.Between groups comparisons were performed using Wilcoxon rank-sum test for continuous variables and with Fisher exact test for categorical variables.Quality of life scales variations from M6 to M12 were explored using MMRM (Mixed Models for Repeated Measures).95% confidence intervals were calculated and p values below the 0.05 threshold were considered as significant.All calculations were performed using the R software.

Main findings
Between April and October 2020, 107 patients were admitted to the Intensive Care Units across the 10 participating centers and were assessed for study eligibility.Of these, 47 patients were successfully enrolled in the STROMA-CoV-2 cohort and 45 received at least one dose of UC-MSCs.Baseline characteristics upon admission were initially presented in the primary study [1].Furthermore, the flow chart is reported in the Fig. 1.
Findings are detailed in Tables 1, 2 and Fig. 2. Since the first part of the study was published covering followup to day 28 [1], we report in this second part of the study, 4 additional serious adverse events occurring in 3 patients (2 in the UC-MSCs group and 1 in the placebo group) from day 29 to 1 year of follow-up (Tables 1, 2).After 12 months of follow-up, the incidence of adverse events was similar between the groups, with 19 patients (90.5%) in the UC-MSCs group and 20 patients (83.3%) in the placebo group (p = 0.67).Likewise, the occurrence of serious adverse events was comparable, affecting 9 patients (42.8%) in the UC-MSCs group and 9 patients (37.5%) in the placebo group (p = 0.77).
The nature of the adverse events (serious, see Table 2, and non-serious-data not shown) encountered in this second part of the study (follow-up from D29 to 12 months) was comparable to that of the adverse events reported in our first part of the study (follow-up to D28), and mostly related to the spontaneous evolution of severe COVID-19 disease in intensive care patients with a high severity score.Likewise, the distribution of the nature of these events was similar in the 2 groups (UC-MSCs versus placebo), with the majority of these adverse events relating to the evolution of severe COVID-19 disease (sepsis, septic shock, multiple organ failure).Significantly, no adverse events were reported that could be directly attributed to the investigational therapy, demonstrating the favorable safety profile of intravenous UC-MSCs in this context up to 1 year following the end of the treatment.
No differences were observed between the UC-MSCs and the placebo groups in terms of mortality, CT-scan lung morphology, lung and muscle function, gas exchange, 6-MWT performances or quality of life (Table 1 and Fig. 2) at 6 or 12 months after hospital discharge.Mixed models for repeated measures adjusted on age and sex also did not show any difference between UC-MSCs and placebo on either quality of life metrics (data not shown).At the study's end, there were 12 deaths, with 5 (29.4%) in the placebo group and 7 (50%) in the UC-MSCs group (p = 0.29).Although maximal inspiratory force (MIP) at 6 months was higher in the UC-MSCs than in the placebo group (mean ± standard deviation (SD)) 111.3 ± 36.9 versus 86.4 ± 29.9 cmH 2 O (p = 0.0439), this difference was no longer significant at 1 year with 120.6 ± 30.3 versus 86.6 ± 30.3 cmH 2 O, respectively (p = 0.0749).Importantly, no signs of fibrosis progression were detected at the 1-year assessment in any group.The variation in endpoints assessed from month 6 to month 12 also did not differ between the UC-MSCs and placebo groups, except for the variation in plasma bicarbonates levels, which had no clinical relevance (data not shown).
Featuring the evolution of patients with COVID-19-related ARDS, residual ground-glass opacities were observed in 11 patients (45.8%) and 5 patients (26.3%) at 6 and 12 months respectively, with no evidence of profibrotic progression.Pulmonary function test results remained stable between 6-and 12-month assessments, with no significant alterations apart from a carbon monoxide diffusion capacity (DLCO) remaining slightly to moderately impaired at 6 and 12 months ((mean ± SD) 71.0 ± 19.3% and 67.4 ± 9.4% of expected theoretical values, respectively).Arterial blood gas analyses conducted at the 6-month and 1-year follow-up indicated the absence of chronic hypercapnia and no requirement of home oxygen therapy.Assessment of respiratory muscles strength showed that while MIP values   (See figure on next page.)Fig. 2 Comparative analysis of patient-reported outcomes using the medical outcome study 36-item short form survey and the EuroQol 5 dimension 5 level dimensions at 6 and 12 months.A UC-MSCs versus placebo groups are visualized as radar chart.Each of the eight domains is scored on a scale from 0 to 100, with a higher score indicating better health and less impact of health on usual roles.In this radar chart, the central point represents a score of 0, while the outermost boundary corresponds to a score of 100.B and C Bar chart representation depicting the EQ-5D variables at 6 months (B) and at 12 months (C).At the 6-month assessment, 11 patients from the UC-MSCs group and 13 from the placebo group were evaluated (24 patients in global cohort).At the 12-month mark, 7 patients from the UC-MSCs group and 12 from the placebo group were assessed (19 patients in global cohort).EQ-5D EuroQol 5 Dimension 5 Level.M month.UC-MSCs umbilical cord-derived mesenchymal stromal cells.SF-36 36-Item Short Form Survey (mean ± SD) 571 ± 90 m. [6].The SF-36 domains with the most impaired scores at 6 months and 1 year were the physical component, the role physical, the mental component and the role emotional (Fig. 2).These data were confirmed by the EQ-5D score, characterized by a high incidence of mild-to-moderate anxiety and depressive symptoms present in 73.7% of patients at 1 year, matching the incidence of mild-to-moderate pain and discomfort (Fig. 2).

Discussion
This study highlights a favorable safety profile associated with repeated intravenous administration of UC-MSCs up to 1 year after hospital discharge for COVID-19-associated ARDS, including adverse events, mortality, CTscan imaging, pulmonary function tests including active muscle tests and quality of life scores.These safety results are consistent with previous clinical trials involving patients with COVID-19-associated ARDS, and showing a favorable safety profile of intravenous UC-MSCs [7,8].
The incidence of diffuse lung ground-glass opacities persisting 1 year after hospitalization (26.3%) in the context of severe COVID-19-associated pneumonia is in line with the results of a meta-analysis including 3134 patients, in which 21.2% (95CI [15.4-28.4],I 2 = 86.7%)presented with ground-glass opacities 1 year after hospitalization [9].The absence of pulmonary fibrosis observed in our cohort contrasts, however, with the results of this meta-analysis reporting an incidence of fibrosis of 20.6% (95CI [1.0-35.2],I 2 = 91.9%)[9].While prolonged impairment of DLCO has been found in other studies, its persistence at 1 year is in contrast to some studies showing some degree of DLCO recovery between 6 months and 1 year [10].While our study therefore confirms that the persistence of diffuse pulmonary opacities combined with prolonged impairment of DLCO appear to characterize the 1-year course of severe pneumonia associated with COVID-19, the small number of patients included, their inclusion during the first wave and the absence of corticosteroid therapy in our study could explain these discrepancies.Regarding the results of the 6-MWT test, our results mirror those found after non-COVID-related ARDS, with an estimated value of 422 m 1 year after ARDS [11], which remains below the values expected in healthy subjects [12].This impairment therefore does not appear to be specific to COVID-19-associated pneumonia.Results for quality-of-life parameters mirror those observed in a cohort of patients with COVID-19 treated with corticosteroids [13].Regarding the SF-36, mental, emotional and physical components were the most impaired, as previously reported [14].Among the five categories of the EQ-5D, anxiety and pain were the most reported, corroborating the findings of previously published research [15], including studies of non-COVID ARDS [16].Thus, the degree of impairment of quality of life of patients found at 1 year in our study does not seem to diverge from that already reported at 1 year following non-COVID-19 ARDS.
The main limitations of our study are the small sample size, the absence of baseline endpoints and an inclusion selecting severe patients from the first pandemic wave, with a high incidence of invasive mechanical ventilation.Similarly, the absence of patients vaccinated and/or treated with corticosteroids or other immunotherapies may have affected the findings.

Conclusion
This study demonstrates a favorable safety profile of repeated intravenous 3 × 10 6 UC-MSCs/kg in the context of the first French wave of COVID-19-associated moderate-to-severe early ARDS, with no adverse effects observed at 6 and 12 months after hospital discharge.The persistence at 1 year of lung opacities combined with impaired DLCO does not appear to lead to greater functional impairment than that observed 1 year after non-COVID-19 ARDS.
experimental drug and preparing the placebo.JR, MHD, and SL were responsible for statistical analyses of clinical data.AS, AM and JR contributed to the data analysis and manuscript writing.All authors revised the report and read and approved the final version before submission.

Fig. 1
Fig. 1 Flow chart of the trial.ELS extracorporeal life support.UC-MSCs umbilical cord-derived mesenchymal stromal cells

Table 1
Comparative analysis of multi-domain outcomes at 6-and 12-month post-hospital discharge: UC-MSCs versus placebo Data are presented as mean (standard deviation) or number (%), unless indicated otherwise.BS Borg scale.bpm beats per minute.DLCO diffusing capacity for carbon monoxide.FEV1 forced expiratory volume in 1 s.FVC forced vital capacity.HRCT high-resolution computed tomography.MEP maximal expiratory pressure.MIP maximal inspiratory pressure.RV residual volume.SNIP sniff nasal inspiratory pressure.Sp0 2 oxygen pulsed saturation.SVC slow vital capacity.TLC total lung capacity.UC-MSCs umbilical cord-derived mesenchymal stromal cells.VAS visual analogue scale.VC vital capacity.6MWT 6-min walking test *In the placebo group, one patient did not undergo plethysmography **Analyses were conducted comparing UC-MSCs and placebo at both six and twelve months using Wilcoxon rank-sum test for continuous data and Fisher exact test for categorical data

Table 2
Reported serious adverse events after day 28 up to 12 months of follow-up post-hospital discharge